Syntheses of α- and γ-Substituted Amides, Peptides, and Esters of Methotrexate and Their Evaluation as Inhibitors of Folate Metabolism

Journal of Medicinal Chemistry

Volumn 25, Issue 2, 1982, Pages 182-187

  Piper, J R ^a   Montgomery, J A ^a   Sirotnak, F M ^b   Chello, P L ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID; METHOTREXATE DERIVATIVE;

ANIMAL EXPERIMENT; BLOOD AND HEMOPOIETIC SYSTEM; CYTOTOXICITY; DRUG SYNTHESIS; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA L 1210; MOUSE;

AMIDES; ANIMAL; CELLS, CULTURED; ESTERS; FOLIC ACID ANTAGONISTS; LEUKEMIA L1210; METHOTREXATE; MICE; PEPTIDES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0020037138     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00344a018     Document Type: Note

References (38)

1. Most of the synthetic work described in this paper was briefly summarized earlier [J. R. Piper and J. A. Montgomery, “Chemistry and Biology of Pteridines”, Proceedings of the International Symposum on the Chemistry and Biology of Pteridines, 6th, La Jolla, CA, 1978.
2. See Dev. Biochem., 4, 261 (1979)].
3. R. B. Livingston and S. K. Carter, “Single Agents in Cancer Chemotherapy”, IFI/Plenum, New York, 1970, p 130–172.
4. B. A. Chabner and M. Slavik, Ed., Proceedings of the High-Dose Methotrexate Therapy Meeting, Cancer Chemother. Rep., Part 3, 6 (1975).
5. J. F. Holland and O. Glidewell, N. Engl. J. Med., 287, 769 (1972).
6. K. D. Bagshaive, Adv. Cancer Res., 18, 231 (1972).
7. N. Jaffe and D. Traggis Proceedings of the High-Dose Methotrexate Therapy Meeting, Cancer Chemother. Rep., Part 3, pp 31–36.
8. C. B. Pratt, D. Roberts, E. Shanks, and E. L. Warmath Proceedings of the High-Dose Methotrexate Therapy Meeting, Cancer Chemother. Rep., Part 3, pp 13–18.
9. J. R. Bertino, Cancer Res., 39, 293 (1979).
10. J. R. Bertino, Cancer Res., 23, 1286 (1963).
11. J. R. Bertino and D. G. Johns, Annu. Rev. Med., 18, 27 (1967).
12. F. M. Sirotnak, D. M. Dorick, and D. M. Moccio, Cancer Treat. Rep., 60, 547 (1976).
13. R. C. Jackson, D. Niethammer, and F. M. Huennekens, Cancer Biochem. Biophys., 1, 151 (1975).
14. F. M. Huenekens and G. B. Henderson, “Chemistry and Biology of Pteridines”, Proceedings of the International Symposium, 5th, University of Konstanz, Konstanz, Germany, Apr 14–18, 1975, W. Pfleiderer, Ed., Walter de Gruyter, Berlin, 1976, pp 179–196.
15. F. M. Sirotnak and R. C. Donsbach, Cancer Res., 36, 1151 (1976).
16. G. A. Fischer, Biochem. Pharmacol., 11, 1233 (1962).
17. I. D. Goldman Proceedings of the High-Dose Methotrexate Therapy Meeting, Cancer Chemother. Rep., Part 3, pp 63–72.
18. R. A. Bender in Proceedings of the High-Dose Methotrexate Therapy Meeting, Cancer Chemother. Rep., Part 3, pp 73–82.
19. W. D. Ensminger, G. B. Grindey, and J. A. Hoglind, Adv. Cancer Chemother., 1, 61 (1979).
20. M. G. Nair and C. M. Baugh, Biochemistry, 12, 3923 (1973).
21. S. A. Jacobs, R. H. Adamson, B. A. Chabner, C. J. Derr, and D. G. Johns, Biochem. Biophys. Res. Commun., 63, 692 (1975).
22. V. M. Whitehead, Cancer Res., 27, 408 (1977).
23. R. L. Schilsky, B. D. Bailey, and B. A. Chabner, Proc. Natl. Acad. Sci. U.S.A., 77, 2919 (1980).
24. J. R. Piper and J. A. Montgomery, J. Org. Chem., 42, 208 (1977).
25. F. H. C. Stewart, Aust. J. Chem., 20, 365 (1967).
26. A. Rosowsky and C.-S. Yu, J. Med. Chem., 21, 170 (1978).
27. A. Rosowsky, G. P. Beardsley, W. D. Ensminger, H. Lazarus, And C.-S. Yu, J. Med. Chem., 21, 380 (1978)
28. J. D. Warren, R. B. Angier, G. Morton, and A. Rosowsky, Org. Prep. Proced. Int., 12, 191 (1980).
29. A. Rosowsky, H. Lazarus, G. C. Yuan, W. R. Beltz, L. Mangini, H. T. Abelson, E. J. Modest, and E. Frei III, Biochem. Pharmacol., 29, 648 (1980).
30. F. M. Sirotnak, P. L. Chello, J. R. Piper, J. A. Montgomery, and J. I. DeGraw, Most of the synthetic work described in this paper was briefly summarized earlier
31. [J. R. Piper and J. A. Montgomery, “Chemistry and Biology of Pteridines”, Proceedings of the International Symposum on the Chemistry and Biology of Pteridines, 6th, La Jolla, CA, 1978 p 597.
32. F. M. Sirotnak, P. L. Chello, and R. W. Brockman, Methods Cancer Res., 16, 381 (1979).
33. F. M. Sirotnak, P. L. Chello, J. I. Degraw, J. R. Piper, and J. A. Montgomery in “Molecular Actions and Targets for Cancer Chemotherapeutic Agents”, A. C. Sartorelli, Ed., Academic Press, New York, 1981, pp 349–383.
34. D. W. Szeto, Y.-C. Cheng, A. Rosowsky, C.-S. Yu, E. J. Modest, J. R. Piper, C. Temple, Jr., R. D. Elliott, J. D. Rose, J. A. Montgomery, Biochem. Pharmacol., 28, 2633 (1979).
35. F. M. Sirotnak, P. L. Chello, J. R. Piper, and J. A. Montgomery, Biochem. Pharmacol., 27, 1821 (1978).
36. M. C. Kirk, W. C. Coburn, Jr., and J. R. Piper, Biomed. Mass Spectrom., 3, 245 (1976).
37. S.-C.J. Fu, M. Reiner, and T. L. Loo, J. Org. Chem., 30, 1277 (1975).
38. H. Sachs and E. Brand, J. Am. Chem. Soc., 75, 4610 (1958).